TRADR 2X LONG SNPS DAILY ETF (SNPX) Fundamental Analysis & Valuation

NYSEARCA:SNPX • US46092D3439

Current stock price

26.52 USD
-0.05 (-0.19%)
Last:

This SNPX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SNPX Profitability Analysis

1.1 Basic Checks

  • In the past year SNPX has reported negative net income.
  • In the past year SNPX has reported a negative cash flow from operations.
  • SNPX had negative earnings in each of the past 5 years.
  • SNPX had a negative operating cash flow in each of the past 5 years.
SNPX Yearly Net Income VS EBIT VS OCF VS FCFSNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • SNPX's Return On Assets of -84.58% is on the low side compared to the rest of the industry. SNPX is outperformed by 68.92% of its industry peers.
  • SNPX has a Return On Equity of -201.09%. This is in the lower half of the industry: SNPX underperforms 68.73% of its industry peers.
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROIC N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
SNPX Yearly ROA, ROE, ROICSNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • SNPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNPX Yearly Profit, Operating, Gross MarginsSNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SNPX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SNPX has more shares outstanding
  • SNPX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SNPX Yearly Shares OutstandingSNPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
SNPX Yearly Total Debt VS Total AssetsSNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -1.94, we must say that SNPX is in the distress zone and has some risk of bankruptcy.
  • SNPX has a Altman-Z score (-1.94) which is in line with its industry peers.
  • There is no outstanding debt for SNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.94
ROIC/WACCN/A
WACCN/A
SNPX Yearly LT Debt VS Equity VS FCFSNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • SNPX has a Current Ratio of 72.70. This indicates that SNPX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SNPX (72.70) is better than 99.81% of its industry peers.
  • A Quick Ratio of 72.70 indicates that SNPX has no problem at all paying its short term obligations.
  • SNPX has a better Quick ratio (72.70) than 99.81% of its industry peers.
Industry RankSector Rank
Current Ratio 72.7
Quick Ratio 72.7
SNPX Yearly Current Assets VS Current LiabilitesSNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SNPX Growth Analysis

3.1 Past

  • SNPX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.75%, which is quite impressive.
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SNPX will show a small growth in Earnings Per Share. The EPS will grow by 2.96% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNPX Yearly EPS VS EstimatesSNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. SNPX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SNPX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNPX Price Earnings VS Forward Price EarningsSNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNPX Per share dataSNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.96%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SNPX Dividend Analysis

5.1 Amount

  • SNPX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SNPX Fundamentals: All Metrics, Ratios and Statistics

TRADR 2X LONG SNPS DAILY ETF

NYSEARCA:SNPX (3/18/2026, 8:04:00 PM)

26.52

-0.05 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner Change2100.27%
Ins OwnersN/A
Ins Owner Change0%
Market Cap36.86M
Revenue(TTM)N/A
Net Income(TTM)-12.97M
Analysts82.86
Price TargetN/A
Short Float %1.24%
Short Ratio1.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.82
Dividend Growth(5Y)N/A
DP-8.16%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.72
P/tB 5.72
EV/EBITDA N/A
EPS(TTM)-9.81
EYN/A
EPS(NY)-7.17
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS0
BVpS4.64
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 72.7
Quick Ratio 72.7
Altman-Z -1.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.37%
OCF growth 3YN/A
OCF growth 5YN/A

TRADR 2X LONG SNPS DAILY ETF / SNPX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TRADR 2X LONG SNPS DAILY ETF (SNPX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SNPX.


What is the valuation status of TRADR 2X LONG SNPS DAILY ETF (SNPX) stock?

ChartMill assigns a valuation rating of 0 / 10 to TRADR 2X LONG SNPS DAILY ETF (SNPX). This can be considered as Overvalued.


What is the profitability of SNPX stock?

TRADR 2X LONG SNPS DAILY ETF (SNPX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for TRADR 2X LONG SNPS DAILY ETF?

The Earnings per Share (EPS) of TRADR 2X LONG SNPS DAILY ETF (SNPX) is expected to decline by -14.17% in the next year.